Naumann RW, et al. - Researchers focused on recent and ongoing phase III clinical trials that are expected to influence primary therapy in ovarian cancer. For this purpose, they reviewed clinicaltrials.gov. Using these trials, they summarized the objectives and the available data. They found 12 potentially practice-changing, randomized phase III trials in front line ovarian cancer, of which, 10 are ongoing, one was discontinued for futility, and one has been recently reported. The use of maintenance targeted therapy was highlighted in all these trials. They found that there exist multiple ongoing trials in primary ovarian cancer, testing PARP inhibitors, anti-angiogenic agents, immuno-oncology agents, combinations of these agents, and hyperthermic intraperitoneal chemotherapy. Within the next several years, maturation of many of these trials is going to happen and these seem to alter the primary treatment of women with ovarian cancer.